



Marius Bredell

Contact

Marius Bredell

Publications (7)

Riesterer O, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G. Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. *Radiother Oncol* 2020; 150:62-69.

Bredell M, Rordorf T, Kroiss S, Rücker M, Zweifel D, Rostetter C. Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study. *J Oral Maxillofac Surg* 2017; 76:775-784.

Rostetter C, Rordorf T, Essig H, Zweifel D, Schumann P, Rücker M, Bredell M. Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel. *Swiss Dent J* 2017; 127:520-521.

Ernst J, Ikenberg K, Apel B, Schumann D, Huber G, Studer G, Rordorf T, Riesterer O, Rössle M, Korol D, Bredell M. Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. *Oncotarget* 2016; 7:76151-76158.

Brown M, Glanzmann C, Huber G, Bredell M, Rordorf T, Studer G. IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80. *Strahlenther Onkol* 2016; 192:526-36.

Studer G, Linsenmeier C, Riesterer O, Najafi Y, Brown M, Yousefi B, Bredell M, Huber G, Schmid S, Studer S, Zwahlen R, Rordorf T, Glanzmann C. Late term tolerance in head neck cancer patients irradiated in the IMRT era. *Radiat Oncol* 2013; 8:259.

Studer G, Brown M, Bredell M, Graetz K, Huber G, Linsenmeier C, Najafi Y, Riesterer O, Rordorf T, Schmid S, Glanzmann C. Follow up after IMRT in oral cavity cancer: update. *Radiat Oncol* 2012; 7:84.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch